Guidelines and treatment for illicit drug related presentations in emergency departments: A scoping review.
clinical guidelines
emergency department
illicit drug-induced psychosis
pharmacological treatment
psychotic disorders
Journal
Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists
ISSN: 1440-1665
Titre abrégé: Australas Psychiatry
Pays: England
ID NLM: 9613603
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
medline:
12
10
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
This review aimed to identify current pharmacological and non-pharmacological treatment employed in emergency departments (EDs) for the management of patients presenting with illicit drug-related presentations (IDP) and compare current treatments with recommendations provided in guidelines. The review consists of English peer-reviewed journal articles and grey literature published in electronic databases: Ovid MEDLINE, PubMed, Embase Classic+Embase, Ovid Emcare and APA PsycInfo between 2015 and 2022. Twelve studies were identified from the search, with agitation and aggression being the most common presentations, and cannabis being the most prevalent illicit drug. Ventilatory support and restraints were the most reported non-pharmacological interventions while benzodiazepines and antipsychotics were the most commonly prescribed pharmacological agents. Non-coercive de-escalation strategies were recommended in all guidelines, with verbal de-escalation being the initial approach before other interventions, such as medications and restraints. However, de-escalation strategies were not reported in any studies. Pharmacological interventions for patients with IDP and related symptoms were in accordance with guidelines. Use of restraints was identified in included studies with notable lack of reporting of de-escalation strategies which may have been deemed insignificant and not reported. Future research could investigate the appropriateness of restrictive interventions as well as the employment of non-restrictive de-escalation strategies.
Identifiants
pubmed: 37548216
doi: 10.1177/10398562231191671
pmc: PMC10566224
doi:
Substances chimiques
Antipsychotic Agents
0
Benzodiazepines
12794-10-4
Illicit Drugs
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
625-634Déclaration de conflit d'intérêts
DisclosureThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
J Emerg Med. 2018 Apr;54(4):500-506
pubmed: 29500048
Lancet. 2012 Jan 7;379(9810):55-70
pubmed: 22225671
Clin Neuropharmacol. 2016 Jul-Aug;39(4):206-9
pubmed: 27015036
J Emerg Med. 2018 Dec;55(6):799-812
pubmed: 30316619
Australas Psychiatry. 2019 Feb;27(1):14-17
pubmed: 30382752
BMC Pharmacol Toxicol. 2016 May 26;17(1):25
pubmed: 27228985
Toxicol Lett. 2017 Aug 5;277:84-91
pubmed: 28579487
Australas Psychiatry. 2019 Aug;27(4):369-373
pubmed: 31081337
J Med Case Rep. 2016 Sep 06;10(1):242
pubmed: 27599617
Drug Alcohol Depend. 2017 Nov 1;180:171-177
pubmed: 28903079
West J Emerg Med. 2012 Feb;13(1):35-40
pubmed: 22461919
West J Emerg Med. 2015 May;16(3):414-7
pubmed: 25987916
J Psychiatr Pract. 2005 Nov;11 Suppl 1:5-108; quiz 110-2
pubmed: 16319571
JAMA Psychiatry. 2013 Mar;70(3):319-24
pubmed: 23303471
J Emerg Nurs. 2020 Nov;46(6):923-931
pubmed: 32843202
West J Emerg Med. 2012 Feb;13(1):26-34
pubmed: 22461918
J Med Toxicol. 2015 Dec;11(4):415-21
pubmed: 25652342
West J Emerg Med. 2012 Feb;13(1):11-6
pubmed: 22461916
West J Emerg Med. 2012 Feb;13(1):17-25
pubmed: 22461917
Pediatr Emerg Care. 2017 Jul;33(7):451-456
pubmed: 26466148
Cureus. 2022 Oct 18;14(10):e30429
pubmed: 36407224